Search company, investor...
Search

Predict your next investment

Venture Capital
biocity.co.uk/investment/alderley-park-ventures

See what CB Insights has to offer

Investments

128

Portfolio Exits

1

About Alderley Park Ventures

Alderley Park Ventures provides pre-seed and seed capital to startups in the life sciences.

Alderley Park Ventures Headquarters Location

BioHub at Alderley Park Alderley Edge

Cheshire, England, SK10 4TG,

United Kingdom

+44 01625 514000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Alderley Park Ventures News

Maxwellia on course to launch self-care alternatives following £3.2m funding round

Apr 13, 2021

A Cheshire business that aims to transform the UK’s self-care market has secured a £3.2m investment in a funding round led by Manchester-based Praetura Ventures. Maxwellia, which is based at Alderley Park, aims to give people easier and faster access to the treatments they need by converting prescription-only medicines to versions that can be bought in a pharmacy. Founded in 2013 by chief executive Anna Maxwell – a pharmacist with more than 20 years’ experience, Maxwellia specialises in ‘switching’, a process in which prescription-only medication is reclassified and made available over the counter. It already has three applications under assessment with the MHRA, and is currently awaiting approval of its first game changing women’s health product following a public consultation. ‘Switching’ widens the access to medicine, supports self-care and patient wellbeing while reducing the burden on public services such as GPs. It is a rigorous process regulated by the MHRA. Previous well known examples of switches include Nurofen, Canesten and Viagra Connect. Maxwellia says the Government is supportive of encouraging self care and widening access to medicines, as well as promoting the role that pharmacists can play in communities to reduce pressure on the NHS. It has secured investment of £3.2m, with £1.7m coming from Praetura Ventures, the venture capital fund that targets early stage businesses in high growth sectors. Other investors include the Future Fund, Catapult Ventures, Alderley Park Ventures and Biocity, along with individual and angel investors. The business has a robust pipeline, which includes numerous medicines across areas of public health with the greatest unmet need, and it will use the funding to scale up the manufacture and rollout of its drugs following MHRA approval, invest in marketing and expand its team. Anna Maxwell said: “The coronavirus pandemic has shown us clearly that we must take better care of our health. A huge part of that is helping people to better manage their own health more easily and conveniently. “We have a fantastic, untapped network of pharmacists who are highly trained clinical experts and are at the heart of most communities across Britain on our high streets. “As a pharmacist, I have seen first hand how important they are for helping people self care. It is vital more medicines are safely changed from being prescription-only so people can access them following a short consultation with a pharmacist.” She added: “With the new funding round led by Praetura Ventures, we’ll be able to scale up our go-to-market operations for our first product launch and our other pipeline of over-the-counter medication, which will be game changing for those who require more widened access to these drugs. The Praetura team’s understanding of our business and their hands on approach were key factors in us choosing them to lead this investment round.” Praetura's investment in Maxwellia was led by investment manager Sim Singh-Landa and director Dr Andy Round, who becomes a non-executive director. Dr Round said: “It is not often that there is the opportunity to play a part in supporting a business that has the potential to transform healthcare for millions of people across the country. Anna’s vision of making it more convenient for patients to access medication is inspiring and we were delighted to be able to be part of this journey. “As an early-stage investor in exciting businesses in high value and innovative sectors like healthcare, this investment is right in our sweet spot. I believe Maxwellia will make a mark in the pharmaceutical switching market with its revolutionary pipeline.” News Source:

Alderley Park Ventures Investments

128 Investments

Alderley Park Ventures has made 128 investments. Their latest investment was in Maxwellia as part of their Seed VC - II on April 4, 2021.

CBI Logo

Alderley Park Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/8/2021

Seed VC - II

Maxwellia

$4.4M

Yes

3

12/14/2020

Growth Equity

Kinomica

$5.2M

Yes

1

8/3/2018

Seed VC

Nexus Labs

Yes

2

1/20/2017

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

Subscribe to see more

0

Date

4/8/2021

12/14/2020

8/3/2018

1/20/2017

Round

Seed VC - II

Growth Equity

Seed VC

Seed VC

Other Investors

Company

Maxwellia

Kinomica

Nexus Labs

Subscribe to see more

Subscribe to see more

Amount

$4.4M

$5.2M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

2

10

0

Alderley Park Ventures Portfolio Exits

1 Portfolio Exit

Alderley Park Ventures has 1 portfolio exit. Their latest portfolio exit was BiVictriX Therapeutics on August 13, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/13/2021

IPO

$99M

Public

2

Date

8/13/2021

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.